PaxMedica, Inc. (OTC PINK:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 4,423,080 shares of common stock

Company provides update on regulatory progress towards US NDA submission

PaxMedica today announced it has timely filed a formal notice of appeal with the Nasdaq Office of Appeals and Review to reverse the decision of a Nasdaq Hearings Panel to delist the Company from Nasdaq.

PaxMedica provided a corporate update in light of its transition off the NASDAQ stock market, emphasizing this change will not affect the company’s commitment to advancing treatments for neurological disorders.

PaxMedica expects to take immediate action in response to an urgent request for IV suramin from the Ministry of Health (MOH) of Malawi.

PaxMedica today announced it has received an urgent request from the Ministry of Health (MOH) of Malawi, asking for emergency access to IV suramin to avert a potential humanitarian crisis brought on by dwindling supplies of drugs used routinely to save lives in that region of Africa.

PaxMedica today announced the completed execution of its three pivotal registration/validation batches of PAX-101, an IV formulation of suramin.

PaxMedica is pleased to share our vision and progress with the wider community

PaxMedica unveiled a Fireside Chat video featuring Howard Weisman, Chairman and CEO, providing a detailed company update with insights into recent achievements and advancements.

Closing previously announced public offering.

Proceeds to Be Used to Advance Company's Development Programs

Key Updates and Achievements

Randomized clinical trial of low dose suramin intravenous infusions for treatment of autism spectrum disorder.

Marks Important Step Prior to Filing NDA for African Sleeping Sickness

The newly acquired data from RLS will play a crucial role in bolstering PaxMedica's ongoing efforts to support the submission for the approval of PAX-101

As a result of the reverse stock split, each 17 pre-split shares of common stock outstanding were automatically combined and converted into one issued and outstanding share of common stock.

Randomized clinical trial of low dose suramin intravenous infusions for treatment of autism spectrum disorder

• Key Guidance Regarding NDA Filing Obtained

IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

PaxMedica announced its Gold Sponsorship of The BRAIN Foundation's esteemed Synchrony Symposia 2023.

Howard Weisman, Chief Executive Officer, will present a corporate overview on Tuesday, September 12, 2023 at 3:00pm EDT at the Lotte New York Palace Hotel. In addition to the presentation, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conference.

Announces Additional Management Changes; Independent Directors Now Majority of Board

PaxMedica provided a business update and reported financial results for the second quarter 2023, ended June 30, 2023.

The study’s primary endpoint was reached and demonstrated statistically significant and clinically meaningful results - These results pave the way for filing an NDA for the use of PAX-101 (intravenous suramin) for the treatment of African Sleeping Sickness

VoxNova is the first purpose-built limited distribution specialty pharmacy benefit manager that is focused on ASD. The Company’s mission is to provide compassionate care and critical oversight using groundbreaking therapies for the treatment of people living with ASD. Under the agreement, VoxNova will have exclusive access to PaxMedica’s PAX-101 intravenous suramin in the United States for a period of up to seven years.

The management and Board of Directors of PaxMedica are aware of the recent market volatility in the company’s common stock. PaxMedica is not aware of any news that might be relevant to the recent share price fluctuations, however management takes its fiduciary responsibility very seriously, and have engaged the services of Shareholder Intelligence Services LLC (“ShareIntel”) to better understand the investor base and the trading behavior around the company’s securities.

CEO, Howard Weisman, participated in a webcast on Saturday, June 17th, hosted by The BRAIN Foundation. The core content of the webcast was an interview with Mr. Weisman by The BRAIN Foundation’s co-founder, Sarika Agrawal.

PaxMedica has submitted a request to the South African Health Products Regulatory Authority (SAHPRA), seeking approval to conduct a double-blind, placebo-controlled study, PAX-ASD-101. This trial will seek to enroll a total of 30 subjects with confirmed ASD, ages 4 to 18, at multiple sites in South Africa. This is the first new clinical trial on the safety, tolerability, and efficacy of suramin since the Company announced the results of its prior Phase II trial in 2021. Enrollment is expected to begin in Q4 2023, following SAHPRA’s potential approval later this summer.

PaxMedica has entered into an agreement with PoloMar Health to investigate the use of emodin in a clinical program as a potential treatment for patients with autism spectrum disorder.

The eligibility review and final enrollment for the company’s Real World Evidence study (HAT-301) has been completed. Patient eligibility was assessed for inclusion by an Independent Study Adjudication Committee which included a total of three subject matter expert medical reviewers.

PaxMedica provided a business update and reported financial results for the first quarter 2023 ended March 31, 2023.

PaxMedica announced that Chief Executive Officer Howard Weisman will ring the Nasdaq Stock Market closing bell on Wednesday April 19, 2023. This comes to celebrate PaxMedica’s listing of its common shares on the Nasdaq Capital Market in August 2022 and April’s Autism Awareness Month.

PaxMedica provided a business update and reported financial results for the fourth quarter and year ended December 31, 2022.

PaxMedica announced that it held a Scientific Advisory Board meeting on March 10-12, 2023. A number of new members have been added to the board, which consists of many key opinion leaders in autism spectrum disorder (ASD) in the United States.

PaxMedica released a 2022 shareholder letter discussing its recent accomplishments and upcoming milestones.

PaxMedica, Inc. has signed a funding agreement for net proceeds of $3.2 million with Lind Global Partners II, LP, an investment fund managed by The Lind Partners, a New York based institutional fund manager (together “Lind”).

PaxMedica today announced that it will be presenting virtually at the upcoming Virtual Investor Summit on January 26 th .

PaxMedica announced that the Company has launched a newly updated corporate website at www.paxmedica.com .

PaxMedica announced it will be presenting at the Benchmark Company’s 11th Annual Discovery One-on-One Investor Conference to be held Thursday, December 1st, 2022 at the New York Athletic Club in New York City.

PaxMedica announced that the Company has entered into a purchase agreement and registration rights agreement (together, the “Agreement”) for up to $20 million with Lincoln Park Capital Fund, LLC ("Lincoln Park").

PaxMedica provided a business update and reported financial results for the third quarter of 2022, ended September 30, 2022.

PaxMedica announced that it has initiated a Phase 3 trial, HAT-301, as part of its strategic plan to obtain US market approval of PAX-101 (intravenous suramin).

PaxMedica announced the appointment of Dr. Stefan Schwabe MD, PhD as Chief Medical Officer. In this role, Dr. Schwabe will be responsible for overseeing and directing product development activities including pre-clinical, clinical, regulatory and pharmaceutical sciences for PaxMedica’s pipeline products. The initial program underway is targeting antipurinergic drug therapies.